Drug Sponsors

Amneal launches new biosciences unit

Thursday, August 27, 2015

Amneal Pharmaceuticals has launched Amneal Biosciences, a wholly owned subsidiary. Amneal Biosciences will focus exclusively on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics and biosimilars to healthcare providers globally.

[Read More]

Royal DSM reorganizes; 1,000 jobs cut

Wednesday, August 26, 2015

Royal DSM, a global life sciences and materials sciences company, has made adjustments to its organizational and operating model, including a reduction in headcount of 900 to 1,100, half of which will occur in the Netherlands. Those cuts will be fully implemented by the end of 2017.

[Read More]

New Norway Innovation Park opens

Monday, August 24, 2015

The Oslo Cancer Cluster Innovation Park in Norway has opened. A $122.8 million, public-private investment, the Innovation Park brings together the research, healthcare and industry partners in the Oslo oncology value chain with the Ullern High School.

[Read More]

Roche to acquire Kapa Biosystems

Thursday, August 20, 2015

Roche has signed a definitive agreement to acquire Kapa Biosystems, a privately held company based in Wilmington, Mass. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications.

[Read More]